ISDA

Deposition Date 2015-07-31

Release Date 2015-11-11

Last Version Date 2024-03-20

Entry Detail

PDB ID:

5AXP

Keywords:

HYDROLASE/HYDROLASE INHIBITOR

Title:

Crystal structure of the catalytic domain of PDE10A complexed with 1-(2-fluoro-4-(2-oxo-1,3-oxazolidin-3-yl)phenyl)-5-methoxy-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-4(1H)-one

Biological Source:

Source Organism:

Homo sapiens (Taxon ID: 9606)

Host Organism:

Escherichia coli

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

1.95 Å

R-Value Free:

0.23

R-Value Work:

0.17

R-Value Observed:

0.17

Space Group:

P 21 21 21

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A
Gene (Uniprot):PDE10A
Chain IDs:A, B
Chain Length:338
Number of Molecules:2
Biological Source:Homo sapiens

UniProt ID:Q9Y233 EC:3.1.4.17

Ligand Molecules

4LK

Primary Citation

Design and synthesis of a novel 2-oxindole scaffold as a highly potent and brain-penetrant phosphodiesterase 10A inhibitor

Yoshikawa, M, Kamisaki, H, Kunitomo, J, Oki, H, Kokubo, H, Suzuki, A, Ikemoto, T, Nakashima, K, Kamiguchi, N, Harada, A, Kimura, H, Taniguchi, T.Show

Bioorg.Med.Chem. 23 7138 7149 (2015)

PMID: 26494583 DOI: 10.1016/j.bmc.2015.10.002

Abstact

Highly potent and brain-penetrant phosphodiesterase 10A (PDE10A) inhibitors based on the 2-oxindole scaffold were designed and synthesized. (2-Oxo-1,3-oxazolidin-3-yl)phenyl derivative 1 showed the high P-glycoprotein (P-gp) efflux (efflux ratio (ER)=6.2) despite the potent PDE10A inhibitory activity (IC50=0.94 nM). We performed an optimization study to improve both the P-gp efflux ratio and PDE10A inhibitory activity by utilizing structure-based drug design (SBDD) techniques based on the X-ray crystal structure with PDE10A. Finally, 1-(cyclopropylmethyl)-4-fluoro-5-[5-methoxy-4-oxo-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-1(4H)-yl]-3,3-dimethyl-1,3-dihydro-2H-indol-2-one (19e) was identified with improved P-gp efflux (ER=1.4) and an excellent PDE10A inhibitory activity (IC50=0.080 nM). Compound 19e also exhibited satisfactory brain penetration, and suppressed PCP-induced hyperlocomotion with a minimum effective dose of 0.3mg/kg by oral administration in mice.

Legend

Protein

Chemical

Disease

Primary Citation of related structures